Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase II study of IMOxine in renal cell carcinoma opens enrollment

Oct. 29, 2004

Phase I/II trial supports activity of epratuzumab in non-Hodgkin's lymphoma

Oct. 28, 2004

Peregrine discusses Tarvacin IND with FDA

Oct. 28, 2004

New NY-ESO-1-derived peptide and its use reported in a recent patent

Oct. 28, 2004

FDA approval for Campath single-dose vial

Oct. 20, 2004

AERES Biomedical completes humanization of Peregrine's 3G4 antibody

Oct. 20, 2004

Patients receive HGS-ETR1 in new cancer studies

Oct. 18, 2004

CuraGen advances CR-011 for metastatic melanoma

Oct. 18, 2004

Development of mycobacterial cell wall-DNA complex advances

Oct. 13, 2004

MDX-060 receives orphan drug status for Hodgkin's disease

Oct. 11, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...